Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Total Current Liabilities (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Total Current Liabilities for 8 consecutive years, with $69.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 22.83% year-over-year to $69.3 million, compared with a TTM value of $69.3 million through Sep 2025, up 22.83%, and an annual FY2024 reading of $67.2 million, down 3.32% over the prior year.
  • Total Current Liabilities was $69.3 million for Q3 2025 at Bicycle Therapeutics, down from $77.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $77.4 million in Q2 2025 and bottomed at $20.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $52.3 million, with a median of $53.3 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 77.64% in 2022, then fell 19.12% in 2024.
  • Year by year, Total Current Liabilities stood at $36.2 million in 2021, then surged by 47.2% to $53.3 million in 2022, then skyrocketed by 30.36% to $69.5 million in 2023, then fell by 3.32% to $67.2 million in 2024, then increased by 3.05% to $69.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for BCYC at $69.3 million in Q3 2025, $77.4 million in Q2 2025, and $57.6 million in Q1 2025.